Annual report pursuant to Section 13 and 15(d)

Note 12 - Segment Information (Tables)

v3.5.0.2
Note 12 - Segment Information (Tables)
 12 Months Ended
Jun. 30, 2016
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 
 
Year Ended June 30,
 
 
 
201
6
 
 
201
5
 
 
201
4
 
External sales
                        
Biotechnology
   $ 317,340     $ 308,437     $ 285,142  
Clinical Controls
     104,484       77,866       72,621  
Protein Platforms
     77,324       66,249       0  
Inter segment
     (125
)
     (306
)
     0  
Consolidated net sales
   $ 499,023     $ 452,246     $ 357,763  
 
 
Year Ended June 30,
 
 
 
201
6
 
 
201
5
 
 
201
4
 
Operating Income
                        
Biotechnology
   $ 168,613     $ 165,226     $ 162,621  
Clinical Controls
     30,412       23,981       22,976  
Protein Platforms
     3,592       4,469       0  
Segment operating income
     202,617       193,676       185,597  
Costs recognized upon sale of acquired inventory
     (5,431
)
     (6,952
)
     (7,480
)
Amortization of intangibles
     (29,395
)
     (26,169
)
     (10,276
)
Stock based compensation
     (9,430
)
     (5,957
)
     (3,523
)
Acquisition related expenses
     (2,761
)
     (4,519
)
     (2,247
)
Corporate general, selling and administrative expenses
     (5,007
)
     (3,056
)
     (2,321
)
Consolidated operating income
   $ 150,593     $ 147,023     $ 159,750  
                         
Goodwill
                        
Biotechnology
   $ 105,380     $ 115,198     $ 90,872  
Clinical Controls
     106,692       60,601       60,601  
Protein Platforms
     218,810       214,839       0  
Consolidated goodwill
   $ 430,882     $ 390,638     $ 151,473  
                         
Intangible assets, net
                        
Biotechnology
   $ 57,199     $ 68,777     $ 53,778  
Clinical Controls
     86,736       49,130       54,998  
Protein Platforms
     166,589       174,932       0  
Consolidated intangible assets, net
   $ 310,524     $ 292,839     $ 108,776  
                         
Assets
                        
Biotechnology
   $ 387,470     $ 430,524     $ 674,854  
Clinical Controls
     212,649       74,954       66,072  
Protein Platforms
     440,343       444,899       0  
Segment assets
     1,040,462       950,378       740,917  
Corporate cash and available- for- sale investments
     31,255       52,800       60,142  
Corporate property and equipment
     56,195       58,270       60,350  
Corporate, other
     1,669       1,912       1,082  
Consolidated assets
   $ 1,129,581     $ 1,063,360     $ 862,491  
                         
Depreciation and amortization
                        
Biotechnology
   $ 14,196     $ 13,820     $ 10,879  
Clinical Controls
     10,462       7,963       7,205  
Protein Platforms
     16,027       13,364       0  
Segment depreciation and amortization
     40,685       35,147       18,084  
Corporate
     2,079       2,079       1,091  
Consolidated depreciation and amortization
   $ 42,764     $ 37,226     $ 19,175  
                         
Capital purchases
                        
Biotechnology
   $ 14,295     $ 9,794     $ 4,157  
Clinical Controls
     1,780       1,932       5,687  
Protein Platforms
     823       8,179          
Segment capital purchases
     16,898       19,905       9,844  
Corporate
     0       0       3,977  
Consolidated capital purchases
   $ 16,898     $ 19,905     $ 13,821  
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
 
 
Year Ended June 30,
 
 
 
 
201
6
 
 
201
5
 
 
201
4
 
 
External sales
                          
United States
  $ 283,270     $ 245,217     $ 190,359    
U.K.     88,680       68,055       55,144    
Other Europe     51,047       66,022       42,013    
China
      27,205       26,105       18,878    
Other Asia
     24,809       23,806       32,704    
Rest of world
    24,012       23,041       18,665    
Total external sales
   $  499,023     $ 452,246     $ 357,763    
Long-lived assets
                          
United States and Canada
   $ 118,027     $ 119,075     $ 109,790  
 
Europe
     14,423       11,239       8,340    
China
     1,109       1,286       678    
Total long-lived assets
   $ 133,559     $ 131,600     $ 118,808